2021 年第三季度报告 单位：元 币种：人民币 证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------------------------------|------------------|------------------------ ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2021, representing a year-on-year increase of 15%[2]. - The net profit attributable to shareholders was 300 million RMB, up 20% compared to the same period last year[2]. - The company's operating revenue for the first half of 2021 was approximately ¥851.23 million, representing a 71.63% increase compared to ¥495.96 million in the same period last year[25]. - The net profit attributable to shareholders for the same period was approximately ¥231.02 million, a significant increase of 739.25% from ¥27.53 million year-on-year[26]. - The net profit after deducting non-recurring gains and losses reached approximately ¥220.99 million, up 2,722.36% from ¥7.83 million in the previous year[25]. - The net cash flow from operating activities increased by 197.73%, amounting to approximately ¥120.79 million compared to ¥40.57 million in the same period last year[26]. - Basic earnings per share rose to ¥1.31, reflecting a growth of 773.33% from ¥0.15 in the previous year[29]. - The gross profit margin for the reporting period was 74.53%, down from 77.21% in the same period last year, primarily due to price reductions in certain models of artificial lenses and hyaluronic acid products[92]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2022[2]. - The company plans to launch three new products in the next quarter, focusing on advanced medical technologies[2]. - Future guidance estimates a revenue growth of 10-15% for the second half of 2021[2]. - The company has implemented a new digital marketing strategy, aiming to improve customer engagement and retention rates by 20%[2]. - The company holds a leading position in the artificial lens market, with an annual sales volume accounting for approximately 30% of the market usage in China[34]. - The company is committed to becoming a leader in the biomedical materials field through technological innovation and resource integration[33]. Research and Development - Research and development expenses increased by 18%, totaling 150 million RMB, to support innovation initiatives[2]. - The company's R&D investment as a percentage of operating revenue was 8.63%, a decrease of 2.78 percentage points from 11.41% in the previous year[25]. - The company has a comprehensive R&D management system, focusing on internal development and collaboration with leading universities and hospitals to enhance technology and product innovation[54]. - Key technologies include advanced manufacturing processes for hydrogels and intraocular lenses, with several patents filed to protect innovations[55]. - The company continues to invest in R&D to develop new technologies and products, ensuring a competitive edge in the pharmaceutical and medical device sectors[54]. - The company’s R&D expenses for the reporting period amounted to CNY 73.49 million, an increase of 29.90% compared to the previous year, representing 8.63% of total revenue[63][67]. Product Development and Clinical Trials - The company has initiated clinical trials for its fourth-generation organic cross-linked hyaluronic acid product, expanding its product portfolio in the high-end market[37]. - The company is advancing the clinical trials of a new orthokeratology lens product based on its proprietary optical design system[35]. - The company has developed a new pig-derived fibrin adhesive, approved for registration by the National Medical Products Administration, which aids in hemostasis and wound healing across various surgical fields[42]. - The company has received CE certification for its innovative hydrophobic injection molded aspheric intraocular lens products, with clinical trials initiated in China[62]. - The fourth-generation hyaluronic acid product has entered the clinical trial phase, indicating ongoing innovation in product development[81]. Market Opportunities - The ophthalmic market in China shows significant growth potential, with cataract surgeries estimated at 3.32 million in 2020, and a surgical implementation rate of only 2,370 per million people, compared to over 10,000 in developed countries[48]. - Over 600 million people in China are affected by myopia, with a youth myopia rate of 53.6%, indicating a growing demand for corrective products[49]. - The medical aesthetics market in China was valued at approximately 197.5 billion RMB in 2020, accounting for 17% of the global market, with expectations to become the largest market globally[49]. - The market for topical recombinant human epidermal growth factor products was about 690 million RMB in 2020, projected to grow to 1.309 billion RMB by 2026, with a CAGR of approximately 9.84%[50]. - There are over 100 million osteoarthritis patients in China, highlighting a significant treatment opportunity for joint health products[50]. Acquisitions and Partnerships - The company has completed the acquisition of a strategic partner, enhancing its product portfolio and distribution capabilities[2]. - The company holds a 55% stake in Hengtai Vision, gaining exclusive distribution rights for high-end orthokeratology lenses "myOK" and children's myopia management lenses "Beishide" in China[35]. - The company has invested in Hebei Xinshi Kang, acquiring a 60% stake to enhance its product offerings in soft contact lenses with myopia correction and cosmetic attributes[35]. Environmental and Regulatory Compliance - The company has completed the construction of environmental protection facilities, including wastewater treatment and air emission treatment systems, which are operating normally and meeting discharge standards[180]. - The company received environmental impact assessment approvals for its projects, including the expansion of epidermal growth factor production and the international pharmaceutical R&D project in November 2019[183]. - Continuous online monitoring of key pollutants in wastewater and air emissions is conducted, with data subject to supervision by environmental authorities[185]. - The company has established emergency response plans for environmental incidents, filed with the local environmental authority in December 2020[184]. Financial Management and Investments - The company reported a significant increase in investment income, which rose by 93.83% to ¥27,312,009.43 from ¥14,090,703.38 year-on-year[141]. - The total investment scale for ongoing projects amounts to ¥41,050.00 million, with a cumulative investment of ¥22,515.85 million[75]. - The company made a new equity investment of CNY 54 million during the reporting period, while the total equity investment decreased by 13.74% year-on-year[154]. - The net cash outflow from investment activities rose sharply to CNY 801,385,495.61, largely due to effective cash management and investments in time deposits and unsecured promissory notes[146]. Shareholder and Governance - The company has committed to not transferring or entrusting the management of its pre-IPO shares for 36 months from the date of listing on the Shanghai Stock Exchange[191]. - A total of 164.9 million shares are subject to a 12-month lock-up period from the date of listing, and 135.1 million shares are subject to a 36-month lock-up period[198]. - The company has established a limit on the annual transfer of shares by certain shareholders to not exceed 25% of their total holdings during their tenure as directors or senior management[196].

Financial Performance - The company's operating revenue for 2020 was approximately ¥1.33 billion, a decrease of 16.95% compared to ¥1.60 billion in 2019[12]. - The net profit attributable to shareholders for 2020 was approximately ¥230 million, down 37.95% from ¥371 million in 2019[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥206 million, a decrease of 42.25% compared to ¥357 million in 2019[12]. - The net cash flow from operating activities for 2020 was approximately ¥262 million, down 24.89% from ¥349 million in 2019[12]. - The company's total assets at the end of 2020 were approximately ¥6.30 billion, an increase of 2.39% from ¥6.15 billion at the end of 2019[12]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥5.49 billion, a slight increase of 0.66% from ¥5.45 billion at the end of 2019[12]. - Basic and diluted earnings per share for 2020 were both ¥1.30, a decrease of 42.73% from ¥2.27 in 2019[13]. - The overall gross margin for the company was 74.91% in 2020, down from 77.28% in 2019, primarily due to a significant decrease in the revenue share of high-margin hyaluronic acid products[59]. - The company's revenue in the pharmaceutical manufacturing industry reached 2,485.73 billion yuan in 2020, with a year-on-year growth rate of 4.5%[29]. Dividend Policy - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 88,311,050 RMB, which accounts for 38.38% of the net profit attributable to shareholders for 2020[2]. - The total share capital of the company as of the report date is 176,622,100 shares[2]. - The company does not plan to increase capital reserves or issue bonus shares[2]. - The company has not made any adjustments to its cash dividend policy during the reporting period[162]. - The cash dividend distribution for the 2018 fiscal year was 5.00 RMB per 10 shares, totaling 80,022,650.00 RMB, which was 19.30% of the net profit attributable to shareholders[164]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.49% in 2020, up from 7.24% in 2019, reflecting a rise of 2.25 percentage points[13]. - The group’s R&D expenses amounted to CNY 126.47 million, an increase of CNY 10.40 million or 8.96% compared to the previous year, with R&D expenses accounting for 9.49% of operating income, up from 7.24%[42][44]. - The company continues to invest in R&D, collaborating with universities and research institutions to advance new technologies and product development[34]. - The company has established four major technology platforms, including artificial lenses and medical chitosan, with leading industry technology levels and independent intellectual property rights[52]. - The company has a comprehensive range of products from basic foldable monofocal intraocular lenses to high-end foldable multifocal lenses, establishing itself as a leader in the domestic intraocular lens field[37]. Market Position and Product Development - The company is the largest producer of orthopedic joint cavity viscoelastic supplements in China, with a market share increase from 39.67% to 42.06% over six consecutive years[32]. - The company holds a 45.85% market share in the ophthalmic viscoelastic agent sector, maintaining this position for 13 years[31]. - The company’s recombinant human epidermal growth factor product has captured a market share of 23.49%, ranking second in the market and narrowing the gap with the leader[32]. - The company is the leading manufacturer of surgical anti-adhesion products in China, with a market share of 29.64% for 13 consecutive years[32]. - The company has established four major product lines in ophthalmology, medical aesthetics, wound care, and orthopedics, focusing on innovative medical products[19]. Operational Risks and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The board of directors has ensured the accuracy and completeness of the annual report[2]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[3]. - The report includes a comprehensive discussion of operational risks and factors affecting performance[3]. - There are no non-operating fund occupations by controlling shareholders or related parties[3]. Strategic Acquisitions and Partnerships - The company acquired a 63.64% stake in Euro-Medical Technology in February 2021, expanding its medical aesthetics product line into RF and laser medical devices[21]. - The company has obtained exclusive rights to distribute Eirion's innovative botulinum toxin products in Greater China, marking its entry into the botulinum toxin and small molecule drug markets[21]. - The company initiated a strategic partnership to acquire 55% of Hengtai Vision for a total of CNY 25 million, enhancing its position in the myopia management market[67]. Compliance and Corporate Governance - The company has committed to a profit distribution policy since April 3, 2019, which is effective indefinitely[173]. - The company reported a commitment to avoid any form of fund occupation by its controlling shareholders and related parties, effective from April 3, 2019, and this commitment is long-term valid[172]. - The company will maintain compliance with the Company Law and Securities Law of the People's Republic of China in all its operations and transactions[171]. - The company has established measures to stabilize its stock price, as detailed in its prospectus under investor protection commitments[172]. Employee and Supplier Relations - The company emphasizes employee development by providing diverse training programs and has established a comprehensive training management system[195]. - The company adheres to GMP and ISO standards in supplier selection to ensure product quality and mitigate supply chain risks[198]. - The company conducts regular customer satisfaction surveys to gather feedback and improve product and service quality[200]. - The company actively engages with suppliers to maintain a fair and transparent procurement process, protecting supplier rights[198].

Financial Performance - Operating revenue for the period was ¥382,585,206.31, representing a significant increase of 149.05% year-on-year[4] - Net profit attributable to shareholders was ¥96,992,749.11, a turnaround from a loss of ¥24,855,428.82 in the same period last year[4] - Basic earnings per share for the period was ¥0.55, compared to a loss of ¥0.14 per share in the previous year[4] - The company reported a total of ¥3,984,796.31 in non-recurring gains and losses for the period[5] - The company achieved operating revenue of RMB 382.59 million, an increase of RMB 228.97 million or 149.05% compared to the same period last year[11] - The net profit attributable to shareholders was RMB 96.99 million, a turnaround from a loss of RMB 24.86 million in the same period last year[12] - Total operating revenue for Q1 2021 reached RMB 382,585,206.31, a significant increase from RMB 153,614,830.20 in Q1 2020, representing a growth of 149.5%[20] - Net profit for Q1 2021 was RMB 99,315,085.73, compared to a net loss of RMB 28,408,114.30 in Q1 2020, indicating a turnaround in profitability[20] - The company reported a basic earnings per share of RMB 0.55 for Q1 2021, compared to a loss per share of RMB -0.14 in Q1 2020[21] - Total comprehensive income for Q1 2021 was RMB 120,373,389.52, a significant recovery from a loss of RMB -80,366,877.89 in Q1 2020[21] Cash Flow - Net cash flow from operating activities was ¥15,609,445.06, a significant improvement from a negative cash flow of ¥54,461,823.95 in the same period last year[4] - Cash flow from operating activities totaled RMB 375,765,049.92 in Q1 2021, compared to RMB 270,287,164.05 in Q1 2020, showing improved cash generation[24] - In Q1 2021, the net cash flow from operating activities was -30,284,718.27, compared to -28,836,899.02 in Q1 2020, indicating a decline in operational cash flow[26] - The total cash inflow from investment activities was 68,757,274.04, up from 32,979,522.42 in the same period last year, reflecting an increase in investment returns[26] - The net cash flow from investment activities was -190,312,463.07, significantly worse than -43,738,637.18 in Q1 2020, highlighting increased investment expenditures[26] - The total cash flow for the period showed a net decrease of -222,592,297.29, compared to -72,714,182.45 in Q1 2020, reflecting overall financial strain[26] Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,402,802,145.37, an increase of 1.65% compared to the end of the previous year[4] - Current assets totaled ¥3,770,803,864.17, slightly down from ¥3,809,958,571.16 at the end of 2020, indicating a decrease of about 1.02%[16] - Non-current assets increased to ¥2,631,998,281.20 from ¥2,488,746,817.00, reflecting a growth of approximately 5.73%[16] - Total liabilities decreased to ¥547,186,310.43 from ¥564,462,942.74, showing a reduction of approximately 3.06%[17] - Shareholders' equity increased to ¥5,855,615,834.94 from ¥5,734,242,445.42, representing a growth of about 2.11%[17] - The company reported an increase in accounts receivable to ¥365,695,416.59 from ¥333,527,490.76, which is an increase of approximately 9.63%[16] - Inventory levels rose slightly to ¥258,395,227.48 from ¥255,126,944.53, indicating a growth of about 0.89%[16] Research and Development - Research and development expenses accounted for 9.55% of operating revenue, a decrease of 8.91 percentage points from the previous year[4] - Research and development expenses amounted to RMB 36.53 million, representing a growth of 28.82% year-on-year[13] - Research and development expenses increased to RMB 36,527,079.45 in Q1 2021, up from RMB 28,354,664.31 in Q1 2020, reflecting a focus on innovation[20] Shareholder Information - The company had a total of 7,411 shareholders at the end of the reporting period[6] - The top shareholder, Jiang Wei, held 25.17% of the shares, totaling 44,449,000 shares[6] Other Financial Metrics - The weighted average return on equity was 1.75%, compared to -0.46% in the previous year[4] - The company reported a significant decrease in other income by 52.45% to RMB 4.75 million, attributed to reduced government subsidies compared to the previous year[11] - The company recorded investment income of RMB 13,750,368.57 in Q1 2021, a significant increase from RMB 3,351,610.11 in Q1 2020, indicating better investment performance[20] - Sales expenses rose to RMB 122,111,278.28 in Q1 2021, compared to RMB 114,868,235.77 in Q1 2020, indicating increased investment in sales efforts[20] - The company reported a total operating cost of RMB 284,719,567.04 in Q1 2021, up from RMB 193,029,975.02 in Q1 2020, reflecting higher operational expenses[20]

2020 年報 | | | | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 5 | 主席致辭 | | 7 | 管理層討論與分析 | | 24 | 董事會報告 | | 46 | 企業管治報告 | | 67 | 企業社會責任 | | 69 | 董事、監事及高級管理人員簡介 | | 78 | 獨立核數師報告 | | 84 | 綜合損益及其他綜合收益表 | | 86 | 綜合財務狀況表 | | 88 | 綜合權益變動表 | | 90 | 綜合現金流量表 | | 93 | 財務報表附註 | | 185 | 釋義 | | 188 | 技術詞彙 | 公司資料 第四屆董事會 執行董事： 侯永泰博士 （主席） 吳劍英先生 （總經理） 陳奕奕女士 唐敏捷先生 （財務總監） 非執行董事： 游捷女士 黃明先生 獨立非執行董事： 李穎琦女士 姜志宏先生 蘇治先生 楊玉社先生 趙磊先生 第四屆監事會 劉遠中先生 （主席） 楊青女士 唐躍軍先生 魏長征先生 楊林鋒先生 授權代表 黃明先生 趙明璟先生 聯席公司秘書 田敏女士 趙明璟先生 （香港特許秘書公會資深會員） 審計委員會 李穎琦女士（ 主席） 游捷 ...

Financial Performance - The company's operating revenue for 2020 was approximately CNY 1.33 billion, a decrease of 16.95% compared to 2019[12]. - The net profit attributable to shareholders for 2020 was approximately CNY 230 million, down 37.95% from the previous year[12]. - The net profit after deducting non-recurring gains and losses was approximately CNY 206 million, a decrease of 42.25% compared to 2019[12]. - The basic earnings per share for 2020 was CNY 1.30, a decline of 42.73% from 2019[13]. - The company's total assets at the end of 2020 were approximately CNY 6.30 billion, an increase of 2.39% from the end of 2019[12]. - The company's net assets attributable to shareholders at the end of 2020 were approximately CNY 5.49 billion, an increase of 0.66% from the end of 2019[12]. - The company reported a quarterly revenue of CNY 440 million in Q4 2020, showing a positive trend in the latter half of the year[15]. - The company experienced a net loss of approximately CNY 25 million in Q1 2020, indicating challenges at the beginning of the year[15]. - The company achieved a total revenue of RMB 133,145.11 million in 2020, a decrease of RMB 27,087.37 million or 16.91% compared to the previous year[59]. - The overall gross margin for the company was 74.91% in 2020, down from 77.28% in 2019, primarily due to a significant decrease in revenue from high-margin hyaluronic acid products[59]. Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 88,311,050 RMB, which accounts for 38.38% of the net profit attributable to shareholders for 2020[2]. - In 2020, the company distributed cash dividends of 7.00 RMB per 10 shares, totaling 124,044,620.00 RMB, which accounted for 33.46% of the net profit attributable to shareholders[155]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.49% in 2020, up from 7.24% in 2019[13]. - The R&D expenses for the reporting period amounted to CNY 126.47 million, an increase of CNY 10.40 million, representing a growth rate of 8.96%[42]. - The company has increased its R&D investment to enhance new technology and product development, focusing on collaboration with universities and research institutions[34]. - The company has established a comprehensive R&D system with 270 R&D personnel, accounting for 19.65% of total employees[119]. - The company is actively collaborating with domestic and international universities and research institutions to enhance its R&D capabilities and technology transfer[123]. Market Position and Product Lines - The company has established four major product lines in ophthalmology, medical aesthetics, wound care, and orthopedics, focusing on innovative medical products[19]. - The company is a leading domestic manufacturer of ophthalmic viscoelastic devices and intraocular lenses, with a complete product portfolio covering various materials and optical designs[19]. - The company is the largest domestic producer of orthopedic joint cavity viscoelastic supplements, with a complete range of hyaluronic acid injection products[23]. - The company is the largest producer of surgical anti-adhesion agents in China, with a market share of 29.64% in 2019, maintaining the top position for 13 consecutive years[32]. - The company holds a 45.85% market share in the domestic ophthalmic viscoelastic agent market and nearly 30% in the artificial lens market[64]. Compliance and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company has not violated decision-making procedures for external guarantees[3]. - There are no special arrangements for corporate governance[3]. - The company has committed to measures to compensate for any dilution of immediate returns since April 3, 2019, which is also valid for the long term[166]. Environmental Management - The company reported a total wastewater discharge of 76,092 tons and managed to keep all pollutant emissions within regulatory limits during the reporting period[198]. - The company processed 31.5259 tons of general waste and 44.6409 tons of hazardous waste, demonstrating its commitment to environmental management[198]. - The company has implemented effective waste treatment methods, ensuring compliance with environmental regulations for both wastewater and air emissions[199]. - The company has completed the construction of environmental protection facilities, including wastewater treatment and air emission terminal treatment facilities[200]. Strategic Initiatives - The company aims to enhance the quality of life for Chinese citizens and promote patient recovery, focusing on differentiated development in ophthalmology, aesthetic medicine, orthopedics, and surgery[149]. - The company is actively pursuing investment and acquisition opportunities in the global ophthalmic field to accelerate the localization of the Chinese ophthalmic industry[66]. - The company has established a strategic goal to become a leading domestic and internationally recognized biopharmaceutical enterprise in the field of biomedical materials[150]. - The company will integrate acquired businesses to maximize synergies and improve operational efficiency[151].

Financial Performance - Net profit attributable to shareholders was CNY 112,646,895.39, down 55.13% year-on-year[5] - Operating revenue for the first nine months was CNY 892,155,592.36, representing a decline of 22.06% compared to the same period last year[5] - Basic earnings per share were CNY 0.63, down 59.87% from the previous year[6] - The company reported a total revenue of RMB 892.16 million for the current period, a decrease of RMB 252.55 million or 22.06% compared to the same period last year[16] - The main business revenue was RMB 891.25 million, down RMB 251.71 million or 22.02% year-on-year[16] - The ophthalmology product line generated revenue of RMB 381.80 million, accounting for 42.84% of total revenue, a decrease of 23.88% from the previous year[16] - The orthopedic product line revenue was RMB 224.61 million, representing 25.20% of total revenue, down 11.12% year-on-year[16] - The company reported a total operating cost of ¥317,248,919.13 for Q3 2020, compared to ¥299,886,373.78 in Q3 2019, indicating an increase of approximately 5.5%[27] - The company reported a total comprehensive income of ¥21,558,659.11 for Q3 2020, compared to ¥9,375,995.01 in Q3 2019, indicating an increase of approximately 130%[30] Cash Flow and Investments - The net cash flow from operating activities was CNY 110,051,983.31, a decrease of 45.17% year-on-year[5] - The company reported a net cash outflow from investing activities of CNY -381,425,700.69, primarily due to new investment agreements[20] - The company’s total cash outflow from operating activities was 308,036,938.41 RMB, slightly lower than 310,538,577.16 RMB in the same period of 2019[33] - The company reported a significant decrease in cash received from other operating activities, totaling 12,128,171.10 RMB, down from 25,591,020.00 RMB in the same period of 2019[33] - The company experienced a net cash outflow from investment activities of -53,687,241.10 RMB, compared to a positive cash flow of 68,443,479.99 RMB in the prior year[34] - Cash and cash equivalents at the end of the period stood at 303,326,921.67 RMB, down from 46,332,226.90 RMB in the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,145,082,708.57, a decrease of 0.11% compared to the end of the previous year[5] - The total liabilities increased to CNY 558,874,882.17 from CNY 498,516,864.48 at the end of 2019[23] - The company reported a decrease in accounts receivable to CNY 316,448,358.65 from CNY 381,990,938.69 year-on-year[22] - The company’s total liabilities as of September 30, 2020, were ¥320,395,320.67, compared to ¥177,729,022.12 in the previous year, showing a significant increase[26] - The total equity attributable to shareholders decreased to ¥4,152,760,978.36 from ¥4,287,888,951.10 at the end of 2019[26] Research and Development - Research and development expenses accounted for 9.43% of operating revenue, an increase of 2.49 percentage points compared to the previous year[6] - Research and development expenses for Q3 2020 were ¥27,529,488.77, slightly down from ¥28,105,188.21 in Q3 2019[27] - Research and development expenses for Q3 2020 were ¥8,615,954.67, a decrease from ¥11,799,584.47 in Q3 2019, representing a reduction of about 27%[29] Market and Product Development - The company anticipates a recovery in domestic business, with major product lines showing positive growth trends in the third quarter[17] - The company plans to continue expanding its product offerings and market presence through strategic initiatives and product differentiation[18] - The launch of the third-generation hyaluronic acid product "Hai Mei" occurred on August 7, 2020, aimed at consolidating the company's leadership in the domestic hyaluronic acid market[18] - The company successfully participated in bulk procurement for high-value medical consumables in various provinces, enhancing market share for its intraocular lens products[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,567[8]

Financial Performance - For the six months ended June 30, 2020, the company recorded revenue of approximately RMB 493.61 million, a decrease of approximately RMB 287.00 million or 36.8% compared to RMB 780.61 million in the same period of 2019[7]. - The profit attributable to ordinary equity holders of the company was approximately RMB 27.53 million, down approximately 84.9% from RMB 182.57 million in the same period of 2019[7]. - Basic earnings per share for the period were RMB 0.15, down from RMB 1.14 in the same period of 2019[7]. - The overall gross margin for the reporting period was 77.1%, stable compared to 76.5% in the same period of 2019[11]. - The company reported a net profit for the six months ended June 30, 2020, of RMB 12.11 million, significantly lower than RMB 196.49 million in the prior year[71]. - Total comprehensive income for the period was RMB (32,520,000), reflecting the impact of foreign exchange losses and other comprehensive income adjustments[78]. - The company reported a profit of RMB 182,568 thousand for the period, contributing to total comprehensive income of RMB 202,507 thousand[77]. Revenue Breakdown - Revenue from ophthalmic products was approximately RMB 209.13 million, a decrease of about RMB 134.90 million or 39.2% compared to the same period in 2019[15]. - Revenue from artificial lenses was approximately RMB 116.32 million, down 44.7% compared to the same period in 2019[16]. - Revenue from viscoelastic materials was approximately RMB 63.14 million, a decrease of 19.2% compared to the same period in 2019[16]. - In the aesthetic and wound care segment, the company reported revenue of approximately RMB 75.81 million, a decrease of about 50.7% compared to the same period in 2019, primarily due to the impact of COVID-19[23]. - The orthopedic products generated revenue of approximately RMB 128.92 million, a decrease of about 23.7% compared to the previous year, but showed recovery to nearly 90% of the previous year's revenue in Q2 2020[25]. - Revenue from anti-adhesion and hemostatic products was approximately RMB 68,413 thousand, a decrease of 28.3% compared to RMB 95,468 thousand in the previous year[97]. Research and Development - Research and development expenses amounted to approximately RMB 56.57 million, an increase of approximately RMB 5.25 million or 10.2% compared to RMB 51.32 million in the same period of 2019, with R&D expenses accounting for 11.5% of revenue[7]. - The R&D investment in the ophthalmology product line was approximately RMB 31.88 million, an increase of approximately RMB 7.29 million or 29.6% compared to the previous year, primarily due to multiple ophthalmic projects entering clinical trial stages[7]. - The group is actively developing over ten projects in ophthalmology, with R&D investment in this area amounting to approximately RMB 318.8 million, a 29.6% increase compared to the same period in 2019[32]. - The company is focusing on expanding its ophthalmic business into myopia prevention and refractive correction, addressing a significant market opportunity in China where over 600 million people are myopic[20]. - The company has developed a hydrophobic injection molding process for aspheric intraocular lens products, which has received ethical approval and is set to begin clinical trials[20]. Impact of COVID-19 - The COVID-19 pandemic significantly impacted the company's operations, leading to a temporary halt in many medical services, including ophthalmology outpatient services and elective surgeries[10]. - Revenue across all product lines decreased compared to the same period in 2019, with the first quarter being particularly affected by the pandemic and the Spring Festival holiday[10]. - The second quarter showed signs of gradual recovery as domestic pandemic control measures were effective[10]. - The company is focused on continuing its R&D efforts and adapting to the changing market conditions post-pandemic[10]. Operational Efficiency and Strategy - The company plans to enhance its operational efficiency and core competitiveness through resource integration across R&D, production, sales, and services, particularly focusing on acquired companies[41]. - The company aims to increase R&D investment in innovative products and optimize its product portfolio to maintain a technological lead in ophthalmology, aesthetics, orthopedics, and surgery[41]. - The company is set to launch multiple high-value consumables procurement initiatives, including intraocular lenses, across various provinces and alliances in the second half of 2020[42]. - The company will actively explore new products and indications to achieve synergistic development in its orthopedic product line, solidifying its market leadership in China[46]. Financial Position - The company's current assets totaled approximately RMB 3,827.41 million, a decrease of about RMB 117.96 million compared to the end of 2019[60]. - Current liabilities increased to approximately RMB 504.50 million, up RMB 144.53 million compared to the end of 2019[60]. - The current ratio was approximately 7.59, slightly down from 10.96 at the end of 2019, indicating a stable financial position[60]. - Cash and cash equivalents as of June 30, 2020, were approximately RMB 901.97 million, a decrease of about RMB 42.54 million from RMB 944.51 million as of December 31, 2019[67]. - The company's total liabilities were approximately RMB 651.75 million, resulting in a debt-to-asset ratio of 10.6%, up from 8.1% as of December 31, 2019[67]. Shareholder Information - The board of directors did not recommend the payment of an interim dividend for the six months ended June 30, 2020[8]. - The company declared dividends amounting to RMB 80,023 thousand during the reporting period[77]. - Major shareholders include Jiang Wei, holding 44,449,000 A shares (32.26% of A shares) and 28,800,000 A shares (20.90% of A shares through spouse's interest)[163]. - Prime Capital Management Company Limited holds 4,793,808 H shares, representing approximately 11.97% of the total H shares[167]. Corporate Governance - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[174]. - The company will continue to review and enhance its corporate governance practices to ensure compliance with the Corporate Governance Code[174]. - The audit committee held meetings on March 26, 2020, and April 29, 2020, to review the audited financial statements for the year ended December 31, 2019, and the unaudited financial statements for the three months ended March 31, 2020[175].